Prudential PLC Purchases 138,355 Shares of Johnson & Johnson $JNJ

Prudential PLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 52.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 402,943 shares of the company’s stock after buying an additional 138,355 shares during the quarter. Johnson & Johnson makes up about 0.4% of Prudential PLC’s holdings, making the stock its 28th largest position. Prudential PLC’s holdings in Johnson & Johnson were worth $61,550,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the first quarter worth about $48,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $203.04 on Thursday. The firm has a market capitalization of $489.18 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $203.48. The business’s 50-day moving average price is $187.24 and its 200-day moving average price is $170.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday, October 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.